Menatetrenone (vitamin K2) acts directly on circulating human osteoclast precursors.
It is still not certain what the direct effect of menatetrenone is on osteoclast precursors. In the present study, we investigated whether menatetrenone has a direct effect on circulating osteoclast precursors to influence osteoclast differentiation. Monocytes isolated from human peripheral blood were cultured with receptor-activated NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Menatetrenone or vitamin K1 was then added to the cultures. Geranylgeraniol or phytol (the respective side chain) was also added to the cultures instead of menatetrenone or vitamin K1, respectively. After 7 and 14 days incubation, cultures were evaluated for cytochemical and functional evidence of osteoclast formation. The number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs) and the percentage area of lacunar resorption induced by RANKL and M-CSF were decreased when menatetrenone or geranylgeraniol was added to the cultures. Dose-dependent inhibition of osteoclast formation and lacunar resorption was seen when the cultures were treated with menatetrenone or geranylgeraniol. In contrast, vitamin K1 or phytol did not affect the number of TRAP-positive MNCs nor the percentage area of lacunar resorption. These results indicate that menatetrenone not only influences osteoclast formation via bone stromal cells but also acts directly on circulating osteoclast precursors to influence osteoclast differentiation. These findings also suggest that geranylgeraniol, the side chain of menatetrenone, plays an important role in this inhibitory effect.
D000135:Acid Phosphatase / Q000378:metabolism; D000933:Antifibrinolytic Agents / Q000494:pharmacology*; D001862:Bone Resorption / Q000188:drug therapy*; D002452:Cell Count; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D004224:Diterpenes / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D015726:Giant Cells / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D010010:Osteoclasts / Q000187:drug effects* / Q000201:enzymology; D010836:Phytol / Q000494:pharmacology; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D000071681:Tartrate-Resistant Acid Phosphatase; D010837:Vitamin K 1 / Q000494:pharmacology; D024482:Vitamin K 2 / Q000494:pharmacology*
D000933:Antifibrinolytic Agents; D004224:Diterpenes; D004338:Drug Combinations; D007527:Isoenzymes; D024482:Vitamin K 2; D010836:Phytol; D010837:Vitamin K 1; C017338:geranylgeraniol; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase